ALX Oncology Holdings Inc. (ALXO)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jaume Pons
Employees:
40
866 MALCOLM ROAD, SUITE 100, BURLINGAME, CA 94010
650-466-7125

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Data derived from most recent annual or quarterly report
Market Cap 433.501 Million Shares Outstanding40.59 Million Avg 30-day Volume 151.822 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.36
Price to Revenue0.0 Debt to Equity0.0 EBITDA-123.605 Million
Price to Book Value1.3589 Operating Margin0.0 Enterprise Value96.823 Million
Current Ratio11.52 EPS Growth-1.99 Quick Ratio11.287
1 Yr BETA 1.6583 52-week High/Low 36.25 / 5.82 Profit Margin0.0
Operating Cash Flow Growth-33.9649 Altman Z-Score6.0348 Free Cash Flow to Firm -80.396 Million
View SEC Filings from ALXO instead.

View recent insider trading info

Funds Holding ALXO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALXO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-10-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-07:
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GARCIA PETER S CHIEF FINANCIAL OFFICER

    • Officer
    150,178 2022-08-05 2

    PONS JAUME PRESIDENT & CEO

    • Officer
    • Director
    786,978 2022-08-05 2

    RANDOLPH SOPHIA CHIEF MEDICAL OFFICER

    • Officer
    • Director
    348,396 2022-08-05 2

    PINTO SHELLY VP, FINANCE AND CAO

    • Officer
    98,718 2022-08-05 2

    GOODMAN COREY S

    • Director
    12,004 2022-06-15 1

    NIELSEN JACK

    • Director
    12,004 2022-06-15 1

    LETTMANN JASON

    • Director
    • 10% Owner
    12,004 2022-06-15 3

    HEMRAJANI REKHA

    • Director
    12,004 2022-06-15 1

    CANAMASAS ITZIAR

    • Director
    2,000 2022-06-15 3

    LSV ASSOCIATES, LLC

    LIGHTSTONE VENTURES, L.P.

    LIGHTSTONE VENTURES (A), L.P.

    LSV ASSOCIATES II, LLC

    LIGHTSTONE VENTURES II, L.P.

    LIGHTSTONE VENTURES II (A), L.P.

    CARUSI MICHAEL A

    GEORGE JEAN

    PLAIN HENRY A JR

    • 10% Owner
    4,526,963 2021-12-13 2

    GRAHAM G. WALMSLEY

    • Director
    12,004 2021-06-11 0

    ADELMAN ROBERT J

    VENBIO GLOBAL STRATEGIC FUND, L.P.

    VENBIO GLOBAL STRATEGIC GP, LTD.

    VENBIO GLOBAL STRATEGIC FUND II L.P.

    VENBIO GLOBAL STRATEGIC GP, L.P.

    VENBIO GLOBAL STRATEGIC GP II, L.P.

    VENBIO GLOBAL STRATEGIC GP II, LTD.

    • SEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
    9,799,331 2020-07-21 0

    PIETZKE STEFFEN VP FIN & CHIEF ACCT OFFICER

    • Officer
    3,000 2020-07-21 0

    VIVO CAPITAL IX, LLC

    VIVO CAPITAL FUND IX, L.P.

    VIVO OPPORTUNITY, LLC

    VIVO OPPORTUNITY FUND, L.P.

    • 10% Owner
    4,220,048 2020-07-21 0

    CAFFO NATHAN CHIEF BUSINESS OFFICER

    • Officer
    11,254 2020-07-21 0

    LSV ASSOCIATES, LLC

    LIGHTSTONE VENTURES, L.P.

    LIGHTSTONE VENTURES (A), L.P.

    LIGHTSTONE VENTURES II, L.P.

    LIGHTSTONE VENTURES II (A), L.P.

    LSV ASSOCIATES II, LLC

    CARUSI MICHAEL A

    GEORGE JEAN

    • 10% Owner
    0 2020-07-16 0

    VIVO CAPITAL IX, LLC

    VIVO CAPITAL FUND IX, L.P.

    • 10% Owner
    0 2020-07-16 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 21:45:04 UTC 3.2448 0.5752 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 21:15:03 UTC 3.2448 0.5752 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 20:45:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 20:15:04 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 19:45:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 19:15:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 18:45:05 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 18:15:04 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 17:45:04 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 17:15:04 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 16:45:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 16:15:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 15:45:04 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 15:15:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 14:45:03 UTC 3.2411 0.5789 55000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 14:15:03 UTC 3.2411 0.5789 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 13:45:04 UTC 3.3167 0.5033 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 13:15:03 UTC 3.3167 0.5033 60000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-28 12:45:03 UTC 3.3167 0.5033 50000
    ALX ONCOLOGY HOLDINGS INC ALXO 2022-11-25 22:15:03 UTC 3.3167 0.5033 55000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund ALXO -10560.0 shares, $-85430.4 2022-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments